OnKure Therapeutics, Inc. (OKUR)
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
OnKure Therapeutics, Inc.
NASDAQ:OKURHealthcare · Biotechnology
-2.33%$2.52
AH Close$2.52+0.00%vs close
AH Close$2.52+0.00%vs close
Mkt Cap$102.05M
Float24.9M
O/S40.5M
Inst Own86.1%
SI4.9%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$59.52M
Total Assets$62.12M
Free Cash Flow-$51.87M
Debt & Equity
Debt 1%
Equity 99%
Total Debt$549K
Total Equity$56.18M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in OKUR's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$62.12M
Liabilities$5.93M
Accounts Receivable$0
Accounts Payable$1.43M
Inventory$0
PP&E (Net)$1M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $830K | $0 | $0 | $0 | $50K | $37K |
| Gross Profit | -$830K | $0 | $0 | $0 | -$50K | -$37K |
| Gross Margin | - | - | - | - | - | - |
| Research and Development | $48.26M | $43.8M | $32.12M | $25.86M | $28.12M | $15.91M |
| Selling, General, and Administrative | $14.69M | $10.59M | $4.82M | $3.9M | $11.65M | $3.61M |
| Other | -$830K | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $62.12M | $54.39M | $36.93M | $29.77M | $39.77M | $19.52M |
| Operating Income (EBIT) | -$62.95M | -$54.39M | -$36.93M | -$29.77M | -$39.82M | -$19.55M |
| Operating Margin | - | - | - | - | - | - |
| Interest Expense | $0 | $300K | $0 | $0 | $0 | $0 |
| Interest Income | $3.44M | $2.01M | $1.62M | $254K | $0 | $0 |
| Other Income (Expense) | $3.43M | $1.71M | $1.62M | $254K | $48K | $87K |
| Income Before Tax (EBT) | -$59.52M | -$52.67M | -$35.31M | -$29.51M | -$39.77M | -$19.46M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$59.52M | -$52.67M | -$35.31M | -$29.51M | -$39.77M | -$19.46M |
| Net Income Margin | - | - | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -4.40 | -3.95 | -2.65 | -2.21 | -21.92 | -7.74 |
| Diluted EPS | -4.40 | -3.95 | -2.65 | -2.21 | -21.92 | -7.74 |
| Weighted Average OS | 13.52M | 13.34M | 13.34M | 13.34M | 1.81M | 2.51M |
| EBITDA | -$58.69M | -$51.71M | -$34.75M | -$29.13M | -$39.72M | -$19.43M |
| EBITDA Margin | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $59.05M | $110.76M | $29.88M | $11.54M | $124.66M | $53.61M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $23.01M | $0 |
| Cash and Short-Term Investments | $59.05M | $110.76M | $29.88M | $11.54M | $147.67M | $53.61M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $1.79M | $0 | $0 | $840K | $6.06M | $1.41M |
| Total Current Assets | $60.84M | $113M | $33.77M | $13.62M | $153.73M | $55.02M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $1M | $1.79M | $1.91M | $2.05M | $212K | $69K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $273K | $109K | $58K | $329K | $78K | $127K |
| Total Long-Term Assets | $1.28M | $1.9M | $1.97M | $2.38M | $290K | $196K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $62.12M | $114.91M | $35.73M | $16M | $154.02M | $55.22M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $1.43M | $2.97M | $3.42M | $2.52M | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $1.25M | $3.17M | $1.66M | $1.46M | $6.2M | $4.58M |
| Total Current Liabilities | $5.92M | $10.53M | $7.29M | $5.54M | $6.2M | $4.58M |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $92.72M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $167K | $36K |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $12K | $0 | $129.82M | $64.39M | $444K | $0 |
| Total Long-Term Liabilities | $12K | $549K | $130.29M | $64.88M | $611K | $92.76M |
| Other Liabilities | $0 | $0 | $0 | $0 | $1 | $0 |
| Total Liabilities | $5.93M | $11.08M | $137.58M | $70.42M | $6.81M | $97.34M |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $1K | $1K | $0 | $1K | $3K | $1K |
| Retained Earnings | -$214.24M | -$154.72M | -$102.05M | -$57.07M | -$84.73M | -$44.96M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $34K | $0 |
| Other Stockholders' Equity | $270.42M | $258.55M | $209K | $2.65M | $231.94M | $2.84M |
| Total Equity | $56.18M | $103.83M | -$101.84M | -$54.42M | $147.21M | -$42.12M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $62.12M | $114.91M | $35.73M | $16M | $154.02M | $55.22M |
| Supplementary Data | ||||||
| Total Debt | $549K | $1.08M | $674K | $637K | $0 | $92.72M |
| Net Debt | -$58.5M | -$109.68M | -$29.2M | -$10.91M | -$124.66M | $39.11M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$59.52M | -$52.67M | -$35.31M | -$29.51M | -$39.77M | -$19.46M |
| Depreciation & Amortization | $830K | $662K | $560K | $387K | $50K | $37K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $11.63M | $4.53M | $199K | $48K | $0 | $0 |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$4.54M | -$5.93M | $1.71M | $0 | $0 | $0 |
| Other Working Capital | -$235K | $1.98M | -$1.71M | $2.12M | -$2.8M | $514K |
| Total Working Capital Change | -$4.78M | -$3.95M | $6K | $2.12M | -$2.8M | $514K |
| Other Non-Cash Items | $6K | $316K | $0 | $0 | $4.54M | $378K |
| Net Cash from Operating | -$51.83M | -$51.12M | -$34.55M | -$26.95M | -$37.98M | -$18.54M |
| Investing Activities | ||||||
| Capital Expenditures | -$46K | -$52K | -$246K | -$1.13M | -$198K | -$24K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | -$31.41M | $0 |
| Sales of Investments | $0 | $15.93M | $0 | $44.1M | $8.23M | $7.4M |
| Other Investing Activities | $0 | $0 | $0 | -$44.1M | $0 | $0 |
| Net Cash from Investing | -$46K | $15.87M | -$246K | -$1.13M | -$23.38M | $7.38M |
| Financing Activities | ||||||
| Debt Repaid | - | -$6M | - | - | - | - |
| Common Stock Issuance | $203K | $58.91M | $65K | $340K | $132.41M | $47.27M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$40K | $51.22M | -$723K | -$1.38M | $0 | $0 |
| Net Cash from Financing | $163K | $116.13M | $53.13M | $26.46M | $132.41M | $47.27M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$51.71M | $80.89M | $18.33M | -$1.62M | $71.05M | $36.11M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$51.83M | -$51.12M | -$34.55M | -$26.95M | -$37.98M | -$18.54M |
| Capital Expenditure | -$46K | -$52K | -$246K | -$1.13M | -$198K | -$24K |
| Free Cash Flow | -$51.87M | -$51.17M | -$34.79M | -$28.09M | -$38.18M | -$18.56M |
| Cash at Beginning | $110.76M | $29.88M | $11.54M | $13.16M | $53.61M | $17.5M |
| Cash at End | $59.05M | $110.76M | $29.88M | $11.54M | $124.66M | $53.61M |